Stolzenburg J-U, Truss M C, Rabenalt R, Do M, Pfeiffer H, Bekos A, Neuhaus J, Stief C G, Jonas U, Dorschner W
Klinik und Poliklinik für Urologie, Universitätsklinikum Leipzig.
Urologe A. 2004 Jun;43(6):698-707. doi: 10.1007/s00120-004-0561-2.
During the last decade laparoscopy has become the standard technique in the urologist's armamentarium due to constant technological advancements and refinements. Laparoscopic radical prostatectomy (LRPE), although technically demanding and associated with a considerable learning curve, has become the operative procedure of choice for patients with clinically localized prostate cancer in selected and specialized urologic centers around the globe. However, a major drawback of LRPE is the transperitoneal route of access to the extraperitoneal organ of the prostate. The principal disadvantages of LRPE are potential intraperitoneal complications. Endoscopic extraperitoneal radical prostatectomy (EERPE) is a further advancement of minimally invasive surgery as it overcomes the limitations of LRPE by the strictly extraperitoneal route of access. Based on our growing experience with this procedure we introduce several technical modifications, improvements, and refinements including a nerve-sparing, potency-preserving approach (nEERPE) in an effort to further improve this minimally invasive procedure. We report our short-term follow-up results after 300 procedures. The mean operative times were 115 min without and 150 min with lymph node dissection, in total 140 min (range: 60-260 min). There was no conversion and the transfusion rate was 1.3%. There were three early reinterventions (two bleeding and one hematoma) and five late reinterventions (four symptomatic lymphoceles and one colostomy due to a rectal fistula). Pathological stage was pT2a in 54 patients (18%), pT2b in 87 patients (29%), pT3a in 115 patients (38.3%), pT3b in 40 patients (13.3%), and pT4 in 4 patients (1.3%). Positive surgical margins were found in 9.2% (13/141) of patients with pT2 tumor and 30.3% (47/155) of patients with pT3 tumor. The mean catheterization time was 6.9 days. Six and twelve months postoperatively 86.3 and 89.6% of the patients were completely continent; 9.2% of patients needed 1-2 pads per day and 4.5 and 1.2% of patients needed more than 2 pads per day, respectively. Short-term oncological and functional results of EERPE are at least as favorable as in LRPE while operative times are shorter and complication rates are low. EERPE is a technical advancement because it combines the advantages of a totally extraperitoneal access with the advantages of a minimally invasive procedure.
在过去十年中,由于技术的不断进步和完善,腹腔镜检查已成为泌尿外科医生的标准技术手段。腹腔镜根治性前列腺切除术(LRPE)虽然技术要求高且学习曲线较长,但在全球选定的专业泌尿外科中心,已成为临床局限性前列腺癌患者的首选手术方式。然而,LRPE的一个主要缺点是通过经腹腔途径进入腹膜外的前列腺器官。LRPE的主要缺点是存在潜在的腹腔内并发症。内镜下腹膜外根治性前列腺切除术(EERPE)是微创手术的进一步发展,因为它通过严格的腹膜外途径克服了LRPE的局限性。基于我们在该手术中不断积累的经验,我们引入了几种技术改进、优化和完善措施,包括保留神经、保留性功能的方法(nEERPE),以进一步改进这种微创手术。我们报告了300例手术后的短期随访结果。平均手术时间在不进行淋巴结清扫时为115分钟,进行淋巴结清扫时为150分钟,总计140分钟(范围:60 - 260分钟)。无中转开腹情况,输血率为1.3%。有3例早期再次干预(2例出血和1例血肿)和5例晚期再次干预(4例有症状的淋巴囊肿和1例因直肠瘘行结肠造口术)。病理分期为pT2a的患者有54例(18%),pT2b的患者有87例(29%),pT3a的患者有115例(38.3%),pT3b的患者有40例(13.3%),pT4的患者有4例(1.3%)。pT2期肿瘤患者中9.2%(13/141)和pT3期肿瘤患者中30.3%(47/155)发现手术切缘阳性。平均导尿时间为6.9天。术后6个月和12个月,分别有86.3%和89.6%的患者完全控尿;9.2%的患者每天需要1 - 2片尿垫,4.5%和1.2%的患者每天需要超过2片尿垫。EERPE的短期肿瘤学和功能结果至少与LRPE一样良好,同时手术时间更短,并发症发生率更低。EERPE是一项技术进步,因为它将完全腹膜外途径的优点与微创手术的优点结合在一起。